The Acheivement’s of Proove Bio

News and Media

May 10, 2017 – Proove Release: Proove Publishes Another Study Validating 97% Accuracy of Opioid Risk Technology

Results Published in the Journal of Addiction Research and Therapy Shows Nearly 97% Accuracy in Identifying Patients At-Risk of Prescription Opioid Abuse IRVINE, Calif., May 10, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces a new study validating the...

October 24, 2013 – Proove Release: Proove Sponsors National Take Back Day

Proove Biosciences Announces Sponsorship of National Drug Take Back Day and HC DrugFree IRVINE, CA (PRWEB) October 24, 2013 Proove Biosciences, the leader in personalized pain medication innovation, is proud to be a Silver Sponsor partner of HC DrugFree and...

March 30, 2016 – Proove Release: Proove Expands Sales Force

IRVINE, CA (PRWEB) MARCH 30, 2016 Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, is excited to announce the expansion of its salesforce. Building on record growth, Proove Biosciences is expanding its network of authorized...

April 7, 2015 – Proove Release: Proove Launches Opioid Response Test

(PRWEB) APRIL 07, 2015 Proove Biosciences a commercial and research leader in Personalized Medicine, is excited to announce the launch of Proove Opioid Response - the world’s first clinical laboratory test to predict responders to opioid pain medications. Building on...

February 9, 2016 – Proove Release: Proove Presents Data at Leading Scientific Meeting

(PRWEB) February 19, 2016 Proove Biosciences, Inc., the commercial and research leader in personalized pain medicine, presented findings on the link between genetics and pain at the American Academy of Pain Management's (AAPM) 32nd Annual Meeting. As the only company...

April 25, 2017 – Proove Release: Milestone of the World’s Largest Biobank and Big Data Set in Chronic Pain –

Proove® Announces Huge Milestone for its Proove Nexus™ Big Data Platform Commemorating National DNA Day IRVINE, Calif., April 25, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces that its Proove Nexus™ platform is the World's Largest DNA Pain Biobank and Big...

May 31, 2017 – Proove Release: Preliminary Results from Large Clinical Utility Study of Over 27,000 Patients Shows 90% of Patients Experience Significant Pain Reduction From Decisions Made with Proove Technology

Preliminary Results of 27,659 patients from MOSAIC Trial Demonstrate that Proove® Technology Leads to Better Patient Outcomes IRVINE, Calif., May 31, 2017 /PRNewswire/ -- Proove® Biosciences, Inc. announces preliminary results at the close of a large patient-centered...

October 23, 2015 – Proove Release: Proove Partners with USC to Conduct Research

Proove Biosciences, a commercial and research leader in personalized medicine, is excited to announce their partnership with the Keck Medicine of the University of Southern California(USC) Pain Center to study the genetics of chronic pain. The T.R.O.J.A.N. Study...

July 14, 2015 – Proove Release: Proove Biosciences Presents Research Studies at Neurological Disorders Summit in San Francisco, CA

Irvine, CA (PRWEB) July 14, 2015 Proove Biosciences, a commercial and research leader in Personalized Medicine, recently presented data on three ground-breaking scientific studies at the Neurological Disorders Summit in San Francisco, CA. The Neurological Disorders...

April 23, 2015 – Proove Release: Proove Biosciences Launches World's First Test To Predict Responders To Commonly Prescribed Non-Opioid Pain Medications

The new Proove Non-Opioid Pain Medication Response profile evaluates genetic factors to predict a patient’s response to non opioids before prescribing Irvine, CA (PRWEB) - Proove Biosciences, a commercial and research leader in Personalized Medicine, is excited to...

Video’s

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Get Instant Access to Updates to The Truth about Proove Bio